Loading...
Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer? reply.
Citations
Altmetric:
Abstract
Authors
Affiliation
Description
Date
2018
Publisher
Collections
Keywords
Type
Other
Citation
Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer? reply. 2018, 19(9):E438-E438 Lancet Oncol